Expanding ventricles may detect preclinical Alzheimer disease
Open accessAbstract
Although there are no treatments that slow the progression of Alzheimer disease (AD), therapies aimed at brain amyloid or at other mechanisms are in trials. It will be important to start treatment early in the process to prevent cognitive decline, emphasizing the importance of identifying AD at the earliest stage possible. Early detection of AD may be possible because asymptomatic subjects have amyloid plaques, intraneuronal tangles, and neurodegeneration.1 PET scanning with C-11 Pittsburgh compound B2 found evidence for amyloid accumulation in the brain of about 20% of healthy elders, FDG PET and MRI changes have been described in asymptomatic cognitively normal subjects, which seem to “predict” future cognitive decline and conversion to AD,3 and amyloid, tau, and other biomarkers in CSF of cognitively normal subjects also suggest early AD.4 None of these biomarkers is closely or directly correlated with neuronal loss. Subjects with AD have less brain tissue in the hippocampus5 and other brain regions,6 associated with ventricular enlargement.7 …
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Ventricle enlargement could represent a prodromal feature related to AD that could be used as an early predictor of disease progression.
“Together this result indicates that ventricle enlargement could represent a prodromal feature related to AD that could be used as an early predictor of disease progression (Carlson et al., 2008; Weiner, 2008).”
From Early stage alterations in white matter and decreased functional interhemispheric hippocampal connectivity in the 3xTg mouse model of Alzheimer’s disease. (2019) · cites this paper as Weiner, 2008
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Trajectories of brain loss in aging and the development of cognitive impairment
Carlson, N. E., Moore, M. M., Dame, A., Howieson, D., Silbert, L. C., Quinn, J. F., & Kaye, J. A. (2008) · Neurology · doi:10.1212/01.wnl.0000280577.43413.d9 · Cited by 144 · see citing works
Flagged first, then by citations
Research works printed but not linked: 11
- [1]Price JL, Morris JC. Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease. Ann Neurol. 1999;45:358–368. doi: 10.1002/1531-8249(199903)45:3<358::aid-ana12>3.0.co;2-x. [DOI] [PubMed] [Google Scholar] · DOI
- [2]Mintun MA, Larossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446–452. doi: 10.1212/01.wnl.0000228230.26044.a4. [DOI] [PubMed] [Google Scholar] · DOI · Paper page
- [3]Small GW, Ercoli LM, Silverman DH, et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA. 2000;97:6037–6042. doi: 10.1073/pnas.090106797. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI · Paper page
- [4]Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007;64:343–349. doi: 10.1001/archneur.64.3.noc60123. [DOI] [PubMed] [Google Scholar] · DOI · Paper page
- [5]Fotenos AF, Snyder AZ, Girton LE, Morris JC, Buckner RL. Normative estimates of cross-sectional and longitudinal brain volume decline in aging and AD. Neurology. 2005;64:1032–1039. doi: 10.1212/01.WNL.0000154530.72969.11. [DOI] [PubMed] [Google Scholar] · DOI · Paper page
- [6]Mortimer JA, Gosche KM, Riley KP, Markesbery WR, Snowdon DA. Delayed recall, hippocampal volume and Alzheimer neuropathology: findings from the Nun Study. Neurology. 2004;62:428–432. doi: 10.1212/01.wnl.0000106463.66966.65. [DOI] [PubMed] [Google Scholar] · DOI
- [7]Adak S, Illouz K, Gorman W, et al. Predicting the rate of cognitive decline in aging and early Alzheimer disease. Neurology. 2004;63:108–114. doi: 10.1212/01.wnl.0000132520.69612.ab. [DOI] [PubMed] [Google Scholar] · DOI
- [8]Apostolova LG, Dutton RA, Dinov ID, et al. Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps. Arch Neurol. 2006;63:693–699. doi: 10.1001/archneur.63.5.693. [DOI] [PubMed] [Google Scholar] · DOI · Paper page
- [9]Mueller SG, Weiner MW, Thal LJ, et al. Ways toward an early diagnosis in Alzheimer's disease: The Alzheimer's Disease Neuroimaging Initiative (ADNI) Alzheimer Dementia. 2005;1:55–66. doi: 10.1016/j.jalz.2005.06.003. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI · Paper page
- [11]Green MS, Kaye JA, Ball MJ. The Oregon brain aging study: neuropathology accompanying healthy aging in the oldest old. Neurology. 2000;54:105–113. doi: 10.1212/wnl.54.1.105. [DOI] [PubMed] [Google Scholar] · DOI
- [12]Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183–194. doi: 10.1111/j.1365-2796.2004.01388.x. [DOI] [PubMed] [Google Scholar] · DOI · Paper page
Cited by
Sorted by citations
Trajectories of brain loss in aging and the development of cognitive impairment
Carlson, N. E., Moore, M. M., Dame, A., Howieson, D., Silbert, L. C., Quinn, J. F., & Kaye, J. A. (2008) · Neurology · doi:10.1212/01.wnl.0000280577.43413.d9 · Cited by 144 · see citing works
Chou, Y.-Y., Leporé, N., Avedissian, C., Madsen, S. K., Parikshak, N., Hua, X., Shaw, L. M., Trojanowski, J. Q., Weiner, M. W., Toga, A. W., et al. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2009.02.015 · Cited by 117 · see citing works
Self-citationManno, F. A. M., Isla, A. G., Manno, S. H. C., Ahmed, I., Cheng, S. H., Barrios, F. A., & Lau, C. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00039 · Cited by 49 · see citing works
Ma, D., Holmes, H. E., Cardoso, M. J., Modat, M., Harrison, I. F., Powell, N. M., O’Callaghan, J. M., Ismail, O., Johnson, R. A., O’Neill, M. J., et al. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00011 · Cited by 36 · see citing works
- Authors
- Weiner, M. W.
- Affiliations
- San Francisco VA Medical Center (US)
- Corresponding author
- Weiner, Michael W.
- ORCID
- Weiner, Michael W.
- Venue
- Neurology
- Published
- 2008-03-11
- Volume
- 70
- Issue
- 11
- Pages
- 824-825
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- PMC
- PMC2561217
- OpenAlex
- W2030840329
- Cited by
- 21
- References
- 1
- Citations by year
- 2025: 1 · 2024: 1 · 2022: 1 · 2020: 1 · 2019: 2 · 2018: 1 · 2014: 1 · 2013: 3 · 2012: 2
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (5u01ag024904-10)
- National Institute on Aging (U01-AG-024904, R01AG010897, P01AG012435)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Cerebrospinal fluid and hydrocephalus
- Keywords
- Alzheimer's disease, ventriculomegaly, preclinical Alzheimer's disease, early detection, hippocampal atrophy, brain amyloid, neurodegeneration, cognitive decline, brain atrophy
- MeSH terms
- Alzheimer Disease, Cerebral Ventricles, Humans, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
